Edgewise Therapeutics, Inc. (NASDAQ:EWTX – Get Free Report) was down 6.4% on Thursday . The stock traded as low as $19.55 and last traded at $19.60. Approximately 410,498 shares changed hands during trading, a decline of 53% from the average daily volume of 868,414 shares. The stock had previously closed at $20.94.
Analyst Ratings Changes
EWTX has been the topic of a number of research analyst reports. Royal Bank of Canada restated an “outperform” rating and set a $32.00 price target on shares of Edgewise Therapeutics in a research report on Thursday, July 25th. Wedbush restated an “outperform” rating and issued a $31.00 target price on shares of Edgewise Therapeutics in a research note on Friday, August 16th. Piper Sandler reissued an “overweight” rating and set a $48.00 price target on shares of Edgewise Therapeutics in a research note on Monday, July 1st. Finally, JPMorgan Chase & Co. upped their target price on shares of Edgewise Therapeutics from $30.00 to $31.00 and gave the company an “overweight” rating in a research report on Monday, August 12th. Five research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Edgewise Therapeutics has a consensus rating of “Buy” and a consensus price target of $33.40.
Read Our Latest Stock Analysis on Edgewise Therapeutics
Edgewise Therapeutics Stock Performance
Edgewise Therapeutics (NASDAQ:EWTX – Get Free Report) last posted its quarterly earnings data on Thursday, August 8th. The company reported ($0.34) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.36) by $0.02. Analysts forecast that Edgewise Therapeutics, Inc. will post -1.59 earnings per share for the current year.
Hedge Funds Weigh In On Edgewise Therapeutics
Several institutional investors and hedge funds have recently made changes to their positions in the company. RA Capital Management L.P. bought a new position in shares of Edgewise Therapeutics during the first quarter worth approximately $162,502,000. Novo Holdings A S bought a new stake in Edgewise Therapeutics during the second quarter valued at $114,263,000. Baker BROS. Advisors LP increased its holdings in Edgewise Therapeutics by 87.6% in the first quarter. Baker BROS. Advisors LP now owns 5,840,059 shares of the company’s stock worth $106,523,000 after purchasing an additional 2,727,273 shares in the last quarter. Vanguard Group Inc. boosted its position in shares of Edgewise Therapeutics by 89.0% during the 1st quarter. Vanguard Group Inc. now owns 4,017,433 shares of the company’s stock worth $73,278,000 after purchasing an additional 1,892,053 shares in the last quarter. Finally, Frazier Life Sciences Management L.P. grew its position in Edgewise Therapeutics by 214.2% in the 4th quarter. Frazier Life Sciences Management L.P. now owns 2,667,203 shares of the company’s stock valued at $29,179,000 after purchasing an additional 1,818,181 shares during the period.
About Edgewise Therapeutics
Edgewise Therapeutics, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, EDG-5506, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy.
Recommended Stories
- Five stocks we like better than Edgewise Therapeutics
- Unveiling The Power Of VWAP: A Key Indicator For Traders
- Advance Auto Parts Eyes Long-Term Growth Despite Q2 Hurdles
- Technology Stocks Explained: Here’s What to Know About Tech
- Toll Brothers Stock Up on Q3 Beat: Luxury Homes Drive Growth
- 3 Tickers Leading a Meme Stock Revival
- 4 No-Brainer Stocks to Hold This Fall for Steady Gains
Receive News & Ratings for Edgewise Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edgewise Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.